How To Survive Covid-19 When Your RNA Vaccine Fails or Backfires
In the war against COVID-19, the most experimental of all vaccines, RNA inoculum in place of pathogenic bacteria or viruses, were introduced first and thrust upon military and healthcare workers, as well as the most vulnerable (elderly, African Americans) who are also the least likely to benefit and most likely to experience severe side effects, turning humanity into one giant global guinea pig lab.
When the race to gain licensure for vaccines by the Food & Drug Administration began, health authorities said they expected four of the first seven vaccines to fail. Confusingly, RNA vaccines are also said to be 95% effective.
Three decades of research efforts to produce an RNA vaccine did not produce a successful track record. But an RNA vaccine would now be successfully developed in just a few weeks, if we are to believe the press releases of the vaccine makers (with information about their stock prices at the bottom).
Since many who read this report have already elected to undergo immunization with an RNA vaccine, be forewarned this report may shake your faith in these vaccines.
Rationale for RNA vaccines
The current COVID-19 coronavirus pandemic resulted in renewed attempts to produce an RNA vaccine because this type of vaccine doesn’t introduce a pathogenic virus into a recipient’s body as conventional vaccines do in order to produce protective antibodies. Therefore vaccine-induced infection cannot occur. RNA vaccines send the same genetic signal to produce antibodies within living cells without actually having to infect patients with an attenuated (weakened) virus or viral particle. And RNA vaccines do not include toxic adjuvants like aluminum to provoke an immune response.
RNA vaccines not as advertised
Regardless of the advertised effectiveness of these RNA vaccines against COVID-19 coronavirus, there is only a remote chance anyone will benefit from these vaccines. Thousands of people must be vaccinated who don’t have any infection to find a few subjects with active cases of COVID-19 infection, among whom protective antibodies will then be produced.
A phase 3 study of an experimental COVID-19 vaccine is revealing. Among over 43,000 total participants (half given the RNA-vaccine and half an inactive placebo shot, or about 21,000 in each group) only 170 cases (4/10ths of one-percent) of infection were tabulated using the woefully inaccurate PCR swab test that produces >50% false positives, with 162 cases in the placebo group and 8 cases of infection in the vaccine group, for a reported effectiveness of 94%.
The RNA vaccinated subjects experienced broad activation of antibodies and T-cells. Presumably 154 cases of infection would have occurred in the vaccine group out of ~21,000 vaccinated, which is only 7/10ths of one-percent.
The mistaken presumption is that the vaccinated participants will have developed long-term immunity against this dreaded virus as most school children do when they are inoculated against measles, chicken pox, etc. Even if these inoculated individuals weren’t exposed to COVID-19 during a study period, they would be protected against future infection.
However, now investigators report there is no immunity against newly mutated forms of COVID-19 that are now overtaking earlier genetic strains.
A former FDA commissioner has recently warned that experimental vaccines now under evaluation do not protect against COVID-19 coronavirus variants (mutations).
So immunized subjects may be re-infected.
As new genetic strains of COVID-19 take over, immunity may be fleeting and vaccinated individuals would have only developed temporary immunity and transiently benefited from vaccination.
Adverse reactions from RNA vaccines
Vaccine makers are declaring their RNA vaccines “safe” before that fact is proven. Among the first 1,893,360 first doses of Pfizer COVID-19 administered, there were 4,393 adverse events (about 2/10ths of one-percent), some life threatening. Those who experienced a serious side effect risked their lives for temporary immunity against a dreaded virus whereas 95-99% of people who acquire this infection get well on their own. The safety reports the public reads about in the news media is smoke and mirrors.
Side effects of RNA vaccines are expected to be latent, months to years after initial inoculation. Some vaccines have been recalled long after gaining FDA approval.
How RNA vaccines went from unsafe to qualified safe.
Early experimental RNA vaccines in the 1990s produced a vexing overreactive immune response in animals. Then in 2005 researchers believe they overcame the early recognized problems by replacing one of the components of RNA vaccine (pseudo-uridine in place of uridine) to weaken immune sensitivity which supposedly improves safety. But weakened vaccination is imperfect vaccination.
Imperfect vaccination resulting from “leaky vaccines” wherein a virus escapes immune surveillance is a known problem. Did the investigators in their zeal to develop a less problematic RNA vaccine end up producing a leaky vaccine?
An imperfect vaccine keeps infected subjects alive but still allows transmission via shedding of viruses that could result in the circulation of very virulent viruses in a population. The RNA vaccines may suppress symptoms, but not transmission to others, thus making the vaccinated super-spreaders.
A vaccine that eradicates less virulent viral strains may allow more deadly viral mutations to prevail. This is called the “imperfect vaccine” problem. The substitution of pseudo-uridine in place of uridine in RNA vaccines may have created “imperfect vaccination.” Virologists know this but are tight-lipped.
Article from LewRockwell